Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Boehringer Ingelheim
AstraZeneca
Dow
Merck

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,998,467

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,998,467 protect, and when does it expire?

Patent 7,998,467 protects DIFFERIN and is included in one NDA.

This patent has seventeen patent family members in twelve countries.

Summary for Patent: 7,998,467
Title:Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers
Abstract: Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein.
Inventor(s): Mallard; Claire (Mougins, FR), Ferrara; Eve (Valbonne, FR)
Assignee: Galderma Research & Development (Biot, FR)
Application Number:12/076,169
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form; Process;

Drugs Protected by US Patent 7,998,467

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp DIFFERIN adapalene LOTION;TOPICAL 022502-001 Mar 17, 2010 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF ACNE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,998,467

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France05 09493Sep 16, 2005

International Family Members for US Patent 7,998,467

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 057866   Start Trial
Australia 2006290364   Start Trial
Brazil PI0617045   Start Trial
Canada 2622468   Start Trial
China 101262862   Start Trial
China 104013540   Start Trial
European Patent Office 1933827   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Express Scripts
Dow
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.